Last reviewed · How we verify
Limethason (dexamethasone palmitate)
Limethason (generic name: dexamethasone palmitate) is a Corticosteroid drug. It is currently in unknown development.
Limethason works by binding to the glucocorticoid receptor, activating it and triggering a cascade of downstream effects that reduce inflammation and immune response.
Limethason (dexamethasone palmitate) is a corticosteroid medication that targets the glucocorticoid receptor. It is a small molecule that works by binding to the receptor, mimicking the effects of the body's natural glucocorticoids. Limethason is used to treat various inflammatory conditions, but its commercial status and approved indications are unknown. As a corticosteroid, it carries key safety considerations, including potential side effects such as immunosuppression and increased risk of infections. Further research is needed to determine its full scope of use and safety profile.
At a glance
| Generic name | dexamethasone palmitate |
|---|---|
| Drug class | Corticosteroid |
| Target | Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor |
| Therapeutic area | Immunology |
| Phase | unknown |
Mechanism of action
Imagine your body's natural glucocorticoids as a key that unlocks a lock, allowing certain cells to calm down and reduce inflammation. Limethason is a synthetic version of that key, which binds to the lock and triggers the same calming effect, helping to reduce swelling and pain in conditions like arthritis or asthma.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain (NA)
- Dexamethasone Palmitate for Postoperative Pain (NA)
- Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery (NA)
- Dexamethasone Palmitate for PONV After Open Surgery (NA)
- Dexamethasone Palmitate for PONV After Craniotomy (NA)
- PANDORA: Paravertebral AdjuNctive DexamethasOne Palmitate Reducing Chronic Pain After Caridiac Surgery (NA)
- Preemptive Co-infiltration of Dexamethasone Palmitate With Ropivacaine for Postoperative Pain in Major Spinal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Limethason CI brief — competitive landscape report
- Limethason updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Limethason
What is Limethason?
How does Limethason work?
What is the generic name of Limethason?
What drug class is Limethason in?
What development phase is Limethason in?
What does Limethason target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing